首页|期刊导航|中国食品药品监管|药品临床价值评价指标体系研究系统综述

药品临床价值评价指标体系研究系统综述OA

A Systematic Review of Indicator Systems for Clinical Value Evaluation of Drugs

中文摘要英文摘要

目的:系统梳理国内外药品临床价值评价指标体系,为我国药品临床价值评估路径的优化提供科学参考.方法:检索中国知网、万方、维普、PubMed 和 Web of Science 等数据库以及各国家或地区相关机构网站,时间范围设定为各数据源收录起始时间至2025年12月31日,系统收集有关评价指标体系的文献及政策文件,并对其评价范围、评价视角、评价维度及指标等进行梳理与分析.结果:纳入药品临床价值评价指标体系 119个,其中主要国家或地区相关机构制定的评估框架 14个.发表时间分布在2010~2025年,年均发表7.44个,发文总量呈增长趋势.评价范围主要包括普适性、抗肿瘤药品、心血管病药品、儿童药品、中成药等.评价视角主要包括医疗机构视角、社会或公共卫生视角、患者视角等.核心评价维度主要为安全性、有效性及经济性,特异性评价维度包括创新性、适宜性、可及性及其他补充维度.结论:国内外关于药品临床价值评价指标体系的研究日渐成熟.在我国药品综合评价的实践中,仍需探索构建多视角多维度评价指标体系,深入研究特定疾病领域的指标体系,并不断推动评价结果的决策转化.

Objective:This study aims to systematically review domestic and international indicator systems for evaluating the clinical value of drugs,and to provide a scientific reference for optimizing China's approach to clinical value evaluation.Methods:A systematic search was conducted in databases including China National Knowledge Infrastructure(CNKI),Wanfang,VIP,PubMed,and Web of Science,as well as relevant websites in various countries and regions,covering the period from inception of each database to December 31,2025.Literature and policy documents related to evaluation indicator systems were systematically collected,and their evaluation scope,perspectives,dimensions,and indicators were analyzed.Results:A total of 119 clinical value evaluation indicator systems for drugs were included,of which 14 were evaluation frameworks established by major national or regional institutions.Published between 2010 and 2025,the annual output averaged 7.44 publications and showed an overall upward trend.The evaluation scope primarily covered general drugs,anticancer drugs,cardiovascular drugs,pediatric drugs,and traditional Chinese patent medicines.Evaluation perspectives primarily included those of healthcare institutions,society/public health,and patients.Core evaluation dimensions were mainly safety,efficacy,and cost-effectiveness,while specific dimensions included innovation,appropriateness,accessibility,and other supplementary dimensions.Conclusion:Research on clinical value evaluation indicator systems for drugs is maturing both domestically and internationally.In China's practice of comprehensive drug evaluation,further efforts are still needed to explore the construction of multi-perspective and multi-dimensional evaluation indicator systems,conduct in-depth research on indicator systems for specific disease areas,and continuously promote the translation of evaluation results into decision-making.

郭嘉欣;郭翰扬;孙天琪;侯紫雨;姚文兵

中国药科大学国际医药商学院中国药科大学国际医药商学院中国药科大学国际医药商学院中国药科大学国际医药商学院中国药科大学国际医药商学院

医药卫生

药品临床价值评价临床综合评价指标体系评价维度评价视角

clinical value evaluation of drugscomprehensive clinical evaluationindicator systemevaluation dimensionsevaluation perspectives

《中国食品药品监管》 2026 (8)

38-49,12

10.3969/j.issn.1673-5390.2026.08.004

评论